Human Tissues On Demand With Next Generation 3D Bioprinting
Santa Clara Convention Center, CA, USA
Grand Ballroom C
15:20 - 15:40
Bioprinting holds the potential to enable the biofabrication of personalized organs, thus addressing the massive problem of organ waitlists and rejection. By initially focusing on "low-hanging fruit" applications of bioprinting, building off of "early-wins," and collaborating with researchers and industry, we can make a realistic impact today and propel the ecosystem into the future.
Speaker Biography (Tamer Mohamed)
An entrepreneur, engineer, inventor, Tamer currently serves as President and CEO of Aspect Biosystems. Tamer co-founded Aspect in 2013 and has played a leading role in its overall corporate, business, and technology development. Under his leadership, Aspect has secured significant funding, entered strategic collaborations with best-in-class pharmaceutical and biotechnology companies, and developed commercial products. In his previous appointment as Chief Technology Officer of the company, Tamer drove the innovation and development of the company's core technologies and intellectual property. Tamer holds a B.A.Sc. in Biomedical Engineering and M.A.Sc. in Electrical and Computer Engineering from the University of British Columbia.
Company Profile (Aspect Biosystems)
Aspect Biosystems Ltd. is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. Aspect's proprietary Lab-on- a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used to advance and accelerate drug discovery and development, and enable the creation of cutting-edge tissue therapies of the future.